Malignant Solid Tumor Clinical Trials

57 recruitingLast updated: June 17, 2026

There are 57 actively recruiting malignant solid tumor clinical trials across 11 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Houston, Texas, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Malignant Solid Tumor Trials at a Glance

57 actively recruiting trials for malignant solid tumor are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 39 trials, with the heaviest enrollment activity in Shanghai, Houston, and Nashville. Lead sponsors running malignant solid tumor studies include Minghui Pharmaceutical (Hangzhou) Ltd, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, and Peking University Cancer Hospital & Institute.

Browse malignant solid tumor trials by phase

Treatments under study

About Malignant Solid Tumor Clinical Trials

Looking for clinical trials for Malignant Solid Tumor? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.428 enrolled7 locationsNCT07287995
Recruiting
Phase 2

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Malignant Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06629584
Recruiting
Phase 1Phase 2

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Advanced Solid TumorMalignant Solid Tumor
Daiichi Sankyo250 enrolled28 locationsNCT04145622
Recruiting
Phase 2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Shanghai Junshi Bioscience Co., Ltd.410 enrolled1 locationNCT07480733
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech367 enrolled10 locationsNCT06115642
Recruiting
Phase 1Phase 2

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular CarcinomaRefractory Solid TumorPediatric Solid Tumor+3 more
St. Jude Children's Research Hospital64 enrolled2 locationsNCT05468359
Recruiting
Phase 1Phase 2

A Study of TAK-505 in Adults With Solid Tumors

Malignant Solid Tumors
Takeda151 enrolled15 locationsNCT07436728
Recruiting
Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Malignant Solid Tumor
Centre Leon Berard455 enrolled10 locationsNCT04116541
Recruiting
Phase 1Phase 2

A Study of MHB048C in Patients With Advanced Solid Tumors

Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2

A Study of MHB009C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07326488
Recruiting
Phase 1Phase 2

A Study of MHB042C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192107
Recruiting
Phase 1

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Advanced malignant solid tumorsMetastatic Malignant Solid Tumors
Genmab45 enrolled5 locationsNCT06573294
Recruiting
Phase 1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
West China Hospital6 enrolled2 locationsNCT07040943
Recruiting
Phase 1

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.30 enrolled1 locationNCT07262164
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 1Phase 2

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
FindCure Biosciences (ZhongShan) Co., Ltd.33 enrolled1 locationNCT06499350
Recruiting
Phase 1

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer+6 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Recruiting
Phase 2

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.120 enrolled1 locationNCT07028281